Skip to content

Role of Irisin/FNDC5 (rs3480) Single Nucleotide Polymorphism in Breast Cancer

Role of Irisin/FNDC5 (rs3480) Single Nucleotide Polymorphism in Breast Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05876728
Enrollment
100
Registered
2023-05-25
Start date
2023-06-01
Completion date
2024-06-01
Last updated
2023-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Breast cancer is the most frequent cancer in women worldwide. Its incidence is increasing but mortality has decreased in a considerable way due to the combined effect of early detection and improvement in treatment . Irisin is encoded by the FNDC5 gene, whose expression is controlled by the peroxi- some proliferator activated receptor gamma coactivator 1 alpha (PGC-1α). PGC-1α is a transcriptional co-activator which does not bind directly to DNA. Studies indicated that the estrogen-related receptor alpha (ERRα) could be a factor that plays a role in PGC-1α binding to DNA. ERRα is encoded by the ESRRA gene and is an orphan nuclear receptor, which has two domains. One of them allows the interaction with DNA, and the second one with a ligand. The ERRα structure is similar to that of the estrogen receptor alpha (ERα), but this receptor does not bind to natural estrogens. ERRα interacts with a canonical sequence of the estrogen response elements (ERRE). ERRα and ERα could compete with each other to bind to similar DNA elements. Together, ERRα binds to DNA, in complex with PGC-1α, to regulate the activity of genes such as FNDC5 . CA15-3, a high molecular weight glycoprotein (300-450 kDa), is produced by the epithelial ducts and acinic breast cells and is then secreted in milk normally. It has been widely used for the prediction of bone metastases in patients with breast cancer .

Interventions

GENETICGenotyping

Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years

Inclusion criteria

* histologically confirmed breast cancer

Exclusion criteria

* • History of other tumors.

Design outcomes

Primary

MeasureTime frameDescription
find a possible association between irisin gene single nucleotide polymorphism with breast cancer12 months\- find a possible association between irisin gene single nucleotide polymorphism with breast cancer risk and the distribution of its alleles, in relation to many clinical parameters of the cancer group.

Countries

Egypt

Contacts

Primary ContactShimaa B Hemdan, lecturer
shimaabadwy@med.sohag.edu.eg01115894759

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026